Background Although increasing evidence has suggested that an efficacy‐effectiveness gap
exists between clinical trial (CT) and real‐world evidence (RWE), to the authors' knowledge …

The divergence between clinical trial results and real-world outcomes is largely unknown for
many cancer types. The present study aims overall to assess the efficacy–effectiveness gap …

Background Tucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed
therapy approved in combination with trastuzumab and capecitabine for use in patients with …

The number of trials conducted and the number of patients per trial are typically small in
paediatric clinical studies. This is due to ethical constraints and the complexity of the medical …

Background It has been suggested that the results from fragile trials are less likely to
translate into benefit in routine clinical practice. Methods We searched the Food and Drug …

Tóm tắt Mục tiêu: Đánh giá kết quả điều trị chuỗi hóa trị và thuốc kháng EGFR trên bệnh
nhân ung thư phổi giai đoạn muộn. Đối tượng nghiên cứu: BN được chẩn đoán UTPTBN …

Đảng ủy, Ban giám hiệu, Phòng quản lý đào tạo Sau đại học, Bộ môn Ung thư-Trường Đại
học Y Hà Nội. Ban giám đốc Bệnh viện K, Bệnh viện Ung bướu Hà Nội, Trung tâm Y học hạt …

Cette thèse est consacrée aux méthodes statistiques d'extrapolation dans les essais de
recherche de dose en pédiatrie. Dans un premier temps, nous réalisons une revue …

The treatment of non-small cell lung carcinoma (NSCLC) patients with epidermal growth
factor receptor tyrosine kinase inhibitors (EGFR-TKI's), such as gefitinib and erlotinib, was …

Die Verantwortung für die vorliegende Bewertung und für das Bewertungsergebnis liegt
ausschließlich beim IQWiG. Die Bewertung wird zur Veröffentlichung an den G-BA …